Avidity Biosciences, Inc. (RNA) Insider Ownership

Historic Insider Ownership Trends

As of April 28, 2026, the three largest insider holders of RNA are Troy Edward Wilson (Director, 605.55K shares), Troy Edward Wilson (Director, 600.00K shares), Kathleen P. Gallagher (Director, 131.36K shares).

A detailed ownership breakdown for Atrium Therapeutics is not available at this time.
Insider shares in Atrium Therapeutics do not amount to a significant value as of April 28, 2026.
Atrium Therapeutics's count of insider shares amounted to 0 as of April 28, 2026.
Among Atrium Therapeutics's top brass, Kathleen P. Gallagher (Director) was the biggest buyer, purchasing 307.50K shares during the 90-day period from January 28, 2026 to April 28, 2026.
Meanwhile, Michael F Maclean (Chief Financial Officer) topped selling at Atrium Therapeutics, disposing of 721.35K shares over the same 90-day window.

Top Direct Holders

Insider ownership data is derived from the last 60 months of Form 4 SEC filings.

Holder	Position	Shares (Direct)	Shares (Indirect)	Report Date
Troy Edward Wilson	-	0	605,552	08 Aug, 2025
Troy Edward Wilson	-	0	600,000	14 Dec, 2023

* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.

Recent Insider Transactions

Detailed insider trading activity based on Form 4 SEC filings.

Rows:

Download Data

Transaction Date	Insider Name	Security Class	Transaction Type	Shares Traded	Price	Ownership	Code
27 Feb, 2026	Eric Mosbrooker	Common Stock	D	79,413	-	D	D
27 Feb, 2026	Teresa Mccarthy	Common Stock	D	165,296	-	D	D
27 Feb, 2026	Simona Skerjanec	Common Stock	D	6,692	-	D	D
27 Feb, 2026	Tamar Thompson	Common Stock	D	6,692	-	D	D
27 Feb, 2026	Troy Edward Wilson	Common Stock	D	65,091	-	D	D
27 Feb, 2026	Kathleen P. Gallagher	Common Stock	D	80,303	-	D	D
27 Feb, 2026	Jean Jinsun Kim	Common Stock	D	6,692	-	D	D
27 Feb, 2026	W. Michael Flanagan	Common Stock	D	150,365	-	D	D
27 Feb, 2026	Charles Iii Calderaro	Common Stock	D	98,547	-	D	D
27 Feb, 2026	Michael F Maclean	Common Stock	D	133,977	-	D	D
27 Feb, 2026	Troy Edward Wilson	Common Stock	D	13,711	-	I	D
27 Feb, 2026	Tamar Thompson	Stock Option (Right to Buy)	D	10,034	-	D	D
27 Feb, 2026	Simona Skerjanec	Stock Option (Right to Buy)	D	10,034	-	D	D
27 Feb, 2026	Eric Mosbrooker	Stock Option (Right to Buy)	D	177,188	-	D	D
27 Feb, 2026	Teresa Mccarthy	Stock Option (Right to Buy)	D	106,000	-	D	D
27 Feb, 2026	Charles Iii Calderaro	Stock Option (Right to Buy)	D	80,000	-	D	D
27 Feb, 2026	W. Michael Flanagan	Stock Option (Right to Buy)	D	25,000	-	D	D
27 Feb, 2026	Jean Jinsun Kim	Stock Option (Right to Buy)	D	10,034	-	D	D
27 Feb, 2026	Kathleen P. Gallagher	Stock Option (Right to Buy)	D	22,321	-	D	D
27 Feb, 2026	Michael F Maclean	Stock Option (Right to Buy)	D	92,000	-	D	D

Showing 1 to 20 of 297 transactions

Research Tools

Avidity Biosciences, Inc. (RNA) Insider Ownership

Historic Insider Ownership Trends

Top Direct Holders

Recent Insider Transactions

Create an account

Sign In

Reset Password